Trial Profile
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational
- Sponsors Pharmacyclics
- 24 Mar 2020 Results from NCT01105247 and NCT01109069, evaluating Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia, published in the Clinical Cancer Research
- 04 Sep 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results assessing 7-year follow up of ibrutinib in first line and relapsed or refractory patients with chronic lymphocytc leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.